To assess the adequacy and the clinical advantages of our signature over currently used parameters, we performed a decision curve analysis proving that our method showed a significantly improved performance when compared to in-use conventional clinical parameters (i.e., preoperative AFP levels and AJCC pathologic stage), thus indicating a more powerful and dynamic reflection of HCC heterogeneity. This evidence concerns the gene AFP and hepatocellular carcinoma.